非危重成人中平衡晶体液与生理盐水的比较
该单中心、实用性、多轮交叉试验在急诊科将平衡晶体液(乳酸林格氏液或Plasma-Lyte A)与生理盐水按月交替分配,纳入13,347例在急诊接受静脉晶体液并随后住非ICU病房的成人。主要终点住院无天数两组均为中位25天(校正比值比0.98,95%CI 0.92–1.04,P=0.41)。平衡晶体液组30天内主要不良肾脏事件发生率低于生理盐水组(4.7% vs 5.6%;校正比值比0.82,95%CI 0.70–0.95,P=0.01)。作者结论认为在非危重成人中两组的住院无天数无差异。
要点
- 急诊接受静脉晶体液后住非ICU的成人中,平衡晶体液与生理盐水的住院无天数均为中位25天,无差异(校正比值比0.98,95%CI 0.92–1.04,P=0.41)。
- 平衡晶体液组30天内主要不良肾脏事件发生率4.7%,低于生理盐水组的5.6%(校正比值比0.82,95%CI 0.70–0.95,P=0.01)。
- 主要不良肾脏事件为全因死亡、新发肾脏替代治疗或持续性肾功能不全(肌酐升至基线≥200%)的复合终点,于出院或30天时删失,以先发生者为准。
- 急诊中晶体液给药量中位数为1079 ml,88.3%的患者仅接受所分配的晶体液。
适用人群与场景
- 在急诊科接受静脉晶体液治疗并随后住非ICU病房的成人。
诊断标准与关键阈值
- 持续性肾功能不全定义为肌酐水平升高至基线值的≥200%。
处置流程与药物剂量
- 急诊科按日历月分配晶体液类型,整个急诊科在16个月试验期间每月在平衡晶体液与生理盐水之间交叉。
- 平衡晶体液为乳酸林格氏液或Plasma-Lyte A。
研究设计与关键结果
- 单中心、实用性、多轮交叉试验,纳入13,347例在急诊接受静脉晶体液并随后住非ICU病房的成人,急诊晶体液量中位数1079 ml,88.3%的患者仅接受所分配晶体液。
- 主要终点住院无天数两组均为中位25天(校正比值比0.98,95%CI 0.92–1.04,P=0.41)。
- 30天内主要不良肾脏事件平衡晶体液组4.7% vs 生理盐水组5.6%(校正比值比0.82,95%CI 0.70–0.95,P=0.01)。
证据类型、等级与局限
- 证据类型:单中心、实用性、多轮交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在急诊接受静脉液体的非危重成人中,平衡晶体液与生理盐水治疗的住院无天数无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Comparative clinical effects of balanced crystalloids and saline are uncertain, particularly in noncritically ill patients cared for outside an intensive care unit (ICU).
METHODS: We conducted a single-center, pragmatic, multiple-crossover trial comparing balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) with saline among adults who were treated with intravenous crystalloids in the emergency department and were subsequently hospitalized outside an ICU. The type of crystalloid that was administered in the emergency department was assigned to each patient on the basis of calendar month, with the entire emergency department crossing over between balanced crystalloids and saline monthly during the 16-month trial. The primary outcome was hospital-free days (days alive after discharge before day 28). Secondary outcomes included major adverse kidney events within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first.
RESULTS: A total of 13,347 patients were enrolled, with a median crystalloid volume administered in the emergency department of 1079 ml and 88.3% of the patients exclusively receiving the assigned crystalloid. The number of hospital-free days did not differ between the balanced-crystalloids and saline groups (median, 25 days in each group; adjusted odds ratio with balanced crystalloids, 0.98; 95% confidence interval [CI], 0.92 to 1.04; P=0.41). Balanced crystalloids resulted in a lower incidence of major adverse kidney events within 30 days than saline (4.7% vs. 5.6%; adjusted odds ratio, 0.82; 95% CI, 0.70 to 0.95; P=0.01).
CONCLUSIONS: Among noncritically ill adults treated with intravenous fluids in the emergency department, there was no difference in hospital-free days between treatment with balanced crystalloids and treatment with saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SALT-ED ClinicalTrials.gov number, NCT02614040 .).
参考来源
- Self WH, Semler MW, Wanderer JP, et al. Balanced Crystalloids versus Saline in Noncritically Ill Adults. N Engl J Med. 2018. PMID: 29485926. doi:10.1056/NEJMoa1711586
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。